Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers

NCT02907294

Huntington Disease

TERMINATED PHASE1

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers

NCT02111330

Parkinson Disease

COMPLETED PHASE1

Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers

NCT01691924

Parkinson Disease

COMPLETED PHASE1

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

NCT01806896

Huntington's Disease

COMPLETED PHASE2

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

NCT02197130

Huntington's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PBF-999 (5 mg)

5 mg of PBF-999

Group Type EXPERIMENTAL

PBF-999

Intervention Type DRUG

5, 10, 20 and 40 mg of PBF-999

PBF-999 (10 mg)

10 mg of PBF-999

Group Type EXPERIMENTAL

PBF-999

Intervention Type DRUG

5, 10, 20 and 40 mg of PBF-999

PBF-999 (20 mg)

20 mg of PBF-999

Group Type EXPERIMENTAL

PBF-999

Intervention Type DRUG

5, 10, 20 and 40 mg of PBF-999

PBF-999 (40 mg)

40 mg of PBF-999

Group Type EXPERIMENTAL

PBF-999

Intervention Type DRUG

5, 10, 20 and 40 mg of PBF-999

Placebo

Placebo for the 5, 10, 20 and 40 mg dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo for all dosis of PBF-999

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PBF-999

5, 10, 20 and 40 mg of PBF-999

Intervention Type DRUG

Placebo

Placebo for all dosis of PBF-999

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male subjects, 18-45 years (inclusive) of age at the time of enrollment.
2. Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide, in addition to having their female partner use some contraceptive measures until 28 days post-administration.
3. Clinically acceptable blood pressure and pulse rate in supine and standing position. Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
4. Body weight within normal range (Quetelet's index between 19 and 26) expressed as weight (kg) / height (m2).
5. Able to understand the nature of the study and comply with all their requirements.
6. Free acceptance to participate in the study by obtains signed informed consent form approved by the Ethics Committee of the Hospital (CEIC).

Exclusion Criteria

1. History of serious adverse reactions or hypersensitivity to any drug.
2. Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
3. Background or clinical evidence of chronic diseases.
4. Acute illness two weeks before drug administration.
5. Having undergone major surgery during the previous 6 months.
6. Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication.
7. History of alcohol dependence or drug abuse in the last 5 years or daily consumption of alcohol \> 40 g or high consumption of stimulating beverages (\> 5 coffees, teas or coca cola drinks/ day).
8. Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
9. Need of any prescription medication within 14 days prior to the administration of the drug and non prescription medication or herbal medicines within 7 days prior to the administration of the drug.
10. Participation in other clinical trials during the previous 90 days in which an investigational drug or a commercially available drug was tested.
11. Having donated blood during 4 weeks period before inclusion in the study.
12. Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
13. 12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec, bradycardia (\<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
14. Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.
15. History of hepatitis HBV and / or HCV and / or positive serology results which indicate the presence of hepatitis B surface antigen and / or detectable HCV ribonucleic acid (RNA).
16. Positive results from the HIV serology.
17. Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation.
18. Positive results of the drugs at screening period or the day before starting treatment period. A minimum list of 6 drugs will be screened for inclusion: Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the Principal Investigator).
19. Known hypersensitivity to the study drug or the composition of the galenical form.
20. History of psychiatric diseases or epileptic seizures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes